Related Experiment Video

Updated: Jul 8, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Antigenotoxic effect of apigenin against anti-cancerous drugs

Yasir Hasan Siddique1, Tanveer Beg, Mohammad Afzal

  • 1Human Genetics and Toxicology Lab, Section of Genetics, Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University, Aligarh, U.P. 202002, India. yasir_hasansiddique@rediffmail.com

Toxicology in Vitro : an International Journal Published in Association with BIBRA
|January 22, 2008
PubMed

Insights

Apigenin significantly reduces genotoxic damage caused by anti-tumor drugs Mitomycin C and cyclophosphamide. This antioxidant may help prevent secondary tumors in cancer patients undergoing chemotherapy.

Area of Science:

  • Pharmacology
  • Toxicology
  • Oncology

Background:

  • Mitomycin C and cyclophosphamide are established anti-tumor drugs with known genotoxic effects.
  • Genotoxicity in non-tumor cells is a concern due to the risk of secondary tumor induction in cancer patients.
  • Apigenin is recognized for its antioxidant properties and potential health benefits.

Purpose of the Study:

  • To investigate the protective effects of apigenin against the genotoxicity induced by Mitomycin C and cyclophosphamide.
  • To evaluate apigenin's efficacy in mitigating DNA damage and chromosomal abnormalities.
  • To assess apigenin's impact on cell cycle kinetics in the presence of genotoxic agents.

Main Methods:

  • Chromosomal aberration analysis
  • Sister chromatid exchange assays
  • Cell cycle kinetics studies
  • Dose-dependent treatment with apigenin, Mitomycin C, and cyclophosphamide

Main Results:

  • Apigenin treatment demonstrated a significant, dose-dependent reduction in genotoxic damage.
  • Mitomycin C and cyclophosphamide induced chromosomal aberrations and cell cycle disturbances.
  • Apigenin mitigated these genotoxic effects, showing protective activity.

Conclusions:

  • Apigenin exhibits potent chemopreventive properties against genotoxicity induced by common anti-cancer drugs.
  • The findings suggest apigenin can reduce the risk of secondary malignancies associated with chemotherapy.
  • Apigenin represents a potential therapeutic adjunct for cancer patients to minimize drug-induced genotoxic side effects.

More Related Videos

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.